We should also not forget that RVX is not only about ABL. Epigenetics is a  recent arrival on the scene and has quickly become a big thing in many aspects of medical science. Whoever buys RVX becomes the overnight torch bearer. It will carry prestige and create new opportunities for collaborations apart from the intrinsic potential future value of ABL and related molecules. This image factor might appeal to senior management.